Brief: Alphamab Oncology says Jskn003 Granted Breakthrough Therapy Designation For Her2+ Advanced CRC
20/10/2025 02:09
Oct 20 (Reuters) - Alphamab Oncology 9966.HK: JSKN003 GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR HER2+ ADVANCED CRC GRANTED BY CENTER FOR DRUG EVALUATION OF NMPA Further company coverage: 9966.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)